TY - JOUR
T1 - Anticancer and anti-inflammatory properties of ganoderma lucidum extract effects on melanoma and triple-negative breast cancer treatment
AU - Barbieri, Antonio
AU - Quagliariello, Vincenzo
AU - Del Vecchio, Vitale
AU - Falco, Michela
AU - Luciano, Antonio
AU - Amruthraj, Nagoth Joseph
AU - Nasti, Guglielmo
AU - Ottaiano, Alessandro
AU - Berretta, Massimiliano
AU - Iaffaioli, Rosario Vincenzo
AU - Arra, Claudio
PY - 2017/3/1
Y1 - 2017/3/1
N2 - Among the most important traditional medicinal fungi, Ganoderma lucidum has been used as a therapeutic agent for the treatment of numerous diseases, including cancer, in Oriental countries. The aim of this study is to investigate the anti-inflammatory, anticancer and anti-metastatic activities of Ganoderma lucidum extracts in melanoma and triple-negative breast cancer cells. Ganoderma lucidum extracts were prepared by using common organic solvents; MDA-MB 231 and B16-F10 cell lines were adopted as cellular models for triple-negative breast cancer and melanoma and characterized for cell viability, wound-healing assay and measurement of cytokines secreted by cancer cells under pro-inflammatory conditions (incubation with lipopolysaccharide, LPS) and pretreatment with Ganoderma lucidum extract at different concentrations. Our study demonstrates, for the first time, how Ganoderma lucidum extracts can significantly inhibit the release of IL-8, IL-6, MMP-2 and MMP-9 in cancer cells under pro-inflammatory condition. Interestingly, Ganoderma lucidum extracts significantly also decrease the viability of both cancer cells in a time- and concentration-dependent manner, with abilities to reduce cell migration over time, which is correlated with a lower release of matrix metalloproteases. Taken together, these results indicate the possible use of Ganoderma lucidum extract for the therapeutic management of melanoma and human triple-negative breast cancer.
AB - Among the most important traditional medicinal fungi, Ganoderma lucidum has been used as a therapeutic agent for the treatment of numerous diseases, including cancer, in Oriental countries. The aim of this study is to investigate the anti-inflammatory, anticancer and anti-metastatic activities of Ganoderma lucidum extracts in melanoma and triple-negative breast cancer cells. Ganoderma lucidum extracts were prepared by using common organic solvents; MDA-MB 231 and B16-F10 cell lines were adopted as cellular models for triple-negative breast cancer and melanoma and characterized for cell viability, wound-healing assay and measurement of cytokines secreted by cancer cells under pro-inflammatory conditions (incubation with lipopolysaccharide, LPS) and pretreatment with Ganoderma lucidum extract at different concentrations. Our study demonstrates, for the first time, how Ganoderma lucidum extracts can significantly inhibit the release of IL-8, IL-6, MMP-2 and MMP-9 in cancer cells under pro-inflammatory condition. Interestingly, Ganoderma lucidum extracts significantly also decrease the viability of both cancer cells in a time- and concentration-dependent manner, with abilities to reduce cell migration over time, which is correlated with a lower release of matrix metalloproteases. Taken together, these results indicate the possible use of Ganoderma lucidum extract for the therapeutic management of melanoma and human triple-negative breast cancer.
KW - Breast cancer
KW - Cell viability
KW - Curcumin
KW - Cytokines
KW - Ganoderma lucidum
KW - Inflammation
KW - Melanoma
UR - http://www.scopus.com/inward/record.url?scp=85014373266&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85014373266&partnerID=8YFLogxK
U2 - 10.3390/nu9030210
DO - 10.3390/nu9030210
M3 - Article
AN - SCOPUS:85014373266
VL - 9
JO - Nutrients
JF - Nutrients
SN - 2072-6643
IS - 3
M1 - 210
ER -